WeightWatchers to offer compounded version of Novo Nordisk's weight-loss drug
WeightWatchers said on Tuesday it would offer a compounded version of Novo Nordisk's popular obesity drug Wegovy as part of its weight-management programs, sending its shares nearly 47% higher to an over two-month closing high.
Your employer may start covering weight-loss drugs soon
Still, more than a quarter of employers are considering adding coverage for GLP-1 drugs for weight loss in 2025 or 2026, according to a national survey conducted this year by Mercer, a human resources consulting firm.
Not Many Employers Cover GLP-1 Weight Loss Drugs
Fewer than 20% of large employers are covering GLP-1 weight loss drugs like Ozempic, a new KFF analysis shows.
Compounding group sues FDA for removing Lilly's weight loss drug from shortage list
A drug compounding industry group on Monday sued the U.S. Food and Drug Administration over its decision to take Eli Lilly’s blockbuster weight loss and diabetes drugs off its list of medicines in short supply last week.
Despite Heavy Marketing, Most Americans Reject the New Weight-Loss Drugs
A new national survey shows that, despite intense marketing, most Americans do not want the new weight-loss injectables, such as Wegovy and Ozempic. The survey was conducted by Morning Consult for the Physicians Committee for Responsible Medicine,
Popular Weight Loss Drugs Now for Patients With Cancer?
Some oncologists are turning to GLP-1 agents to help patients shed excess pounds, with the goal of improving cancer outcomes. But data on the practice remain limited.
Eli Lilly’s weight-loss and diabetes drugs are no longer in shortage, says FDA
The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage signaling that the company has succeeded in expanding manufacturing.
Lilly weight-loss drug copycats dealt blow as shortage ends
Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the U.S., threatening to upend the many knockoffs that became popular when patients couldn’t find the brand-name medicines.
How biospecimens are advancing the development of weight loss drugs
Explore how pharmaceutical researchers are fueling weight loss drug development using biospecimens to unlock the underlying mechanisms of obesity.
Compounding group sues FDA for removing Lilly’s obesity drug from its shortages list
A trade group representing compounding pharmacies sued the FDA for a “reckless and arbitrary” decision to remove Eli Lilly's tirzepatide from an official shortages list.
Lilly Weight-Loss Drug Copycat Makers Sue FDA Over Shortage End
A group representing companies that made copycat versions of Eli Lilly & Co.’s weight-loss drugs sued the US Food and Drug Administration over the agency’s decision to remove Lilly’s medications from its shortage list.
Weight-loss drugs are life-changing — and expensive. Here's one woman's solution.
A woman who started taking a popular weight loss medication through a clinical trial had to look for alternatives when her ...
Weight loss drugs like Ozempic and Wegovy are tremendously popular and effective. Patients should also be careful in using them
Semaglutide, the underlying drug marketed as Ozempic and Wegovy, works by mimicking a hormone that triggers the body to feel ...
News Medical on MSN10h
Survey: Most Americans skeptical about weight-loss injections
A new national survey shows that, despite intense marketing, most Americans do not want the new weight-loss injectables, such ...
Facebook has become the place to sell leftover Ozempic, other weight loss drugs — as NYC sellers take advantage of shortages and high prices
God knows what volume they’re actually selling. And who knows? You’re just taking it,” one expert told The Post.
Lilly Shells Out $4.5 Billion for New Drug Development Plant
Eli Lilly & Co. is pouring $4.5 billion into a new manufacturing plant in Indiana to make drugs for future clinical trials, ...